In our group ICU mortality was 3.5% and the hospital mortality was 5.6%. The hospital mortality is closely related to the hospital length of stay [52] . Our survival data are similar to other transplant programs [6] [7] [8] with a cumulative patient survival of 89.5% after one year, 84.1% after three years and 74.1% after five years, even though in our study population 38.4% of marginal donor grafts were transplanted. In our study population, the use of marginal liver grafts was associated with higher ICU length of stay, but did not lead to an increased overall mortality [53, 54] and is able to decrease wait list mortality.